Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$535K Buy
+2,916
New +$537K 0.26% 128
2025
Q4
Sell
-17,191
Closed -$2.41M 358
2025
Q3
$2.41M Buy
17,191
+12,666
+280% +$1.71M 0.49% 50
2025
Q2
$568K Buy
+4,525
New +$564K 0.12% 243
2024
Q4
Sell
-5,756
Closed -$1.12M 260
2024
Q3
$1.12M Buy
+5,756
New +$1.2M 0.63% 42
2024
Q2
Sell
-1,389
Closed -$300K 239
2024
Q1
$300K Buy
+1,389
New +$325K 0.17% 176
2023
Q3
Sell
-3,402
Closed -$969K 233
2023
Q2
$969K Buy
+3,402
New +$1.01M 0.87% 28

Other funds holding BIIB

iSAM Funds (UK)'s BIIB Position: Q1 2026 in Review

iSAM Funds (UK) opened a new position in Biogen (BIIB) in Q1 2026: 2,916 shares worth $535K. The stake represents 0.26% of the portfolio and ranks #128 among its holdings. This is a return to the name: iSAM Funds (UK) previously reported a position in BIIB as recently as Q3 2025.

iSAM Funds (UK) first reported a position in BIIB in Q2 2023 and has held it in 6 quarters since. The position peaked at $2.41M in Q3 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • iSAM Funds (UK) held 2,916 shares of Biogen worth $535K as of Q1 2026.
  • Biogen was a new iSAM Funds (UK) position in Q1 2026.
  • Biogen made up 0.26% of iSAM Funds (UK)'s portfolio in Q1 2026, its #128 holding.
  • iSAM Funds (UK) first reported a position in Biogen in Q2 2023 and has held it in 6 quarters since.
  • iSAM Funds (UK)'s Biogen position peaked at $2.41M in Q3 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on iSAM Funds (UK)'s 13F filing for Q1 2026, filed 13 May 2026.